0001209191-20-045145.txt : 20200805 0001209191-20-045145.hdr.sgml : 20200805 20200805165128 ACCESSION NUMBER: 0001209191-20-045145 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200803 FILED AS OF DATE: 20200805 DATE AS OF CHANGE: 20200805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sachdev Amit CENTRAL INDEX KEY: 0001406338 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 201078313 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-03 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001406338 Sachdev Amit C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Patient Officer Common Stock 2020-08-03 4 M 0 1941 86.52 A 37044 D Common Stock 2020-08-03 4 S 0 500 276.96 D 36544 D Common Stock 2020-08-03 4 S 0 690 278.25 D 35854 D Common Stock 2020-08-03 4 S 0 751 279.18 D 35103 D Common Stock 882 I 401(k) Common Stock 14002 I Held in Trust Stock Option (Right to Buy) 86.52 2020-08-03 4 M 0 1941 0.00 D 2027-02-02 Common Stock 1941 3884 D Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $276.96 (range $276.62 to $277.25). Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $278.25 (range $277.73 to $278.48). Open market sales reported on this line occurred at a weighted average price of $279.18 (range $278.92 to $279.61). The option vests in 16 quarterly installments from 02/03/2017. /s/ Sabrina Yohai, Attorney-in-Fact 2020-08-05